Ameriflex Group Inc. Cuts Position in Amgen Inc. $AMGN

Ameriflex Group Inc. decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 95.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 395 shares of the medical research company’s stock after selling 7,450 shares during the quarter. Ameriflex Group Inc.’s holdings in Amgen were worth $110,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of AMGN. Nuveen LLC purchased a new position in Amgen in the first quarter worth $688,868,000. Federated Hermes Inc. raised its position in Amgen by 48.5% in the first quarter. Federated Hermes Inc. now owns 2,037,169 shares of the medical research company’s stock worth $634,680,000 after acquiring an additional 665,555 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Amgen by 128.9% in the first quarter. The Manufacturers Life Insurance Company now owns 1,065,694 shares of the medical research company’s stock worth $332,017,000 after acquiring an additional 600,096 shares in the last quarter. Kingstone Capital Partners Texas LLC purchased a new position in Amgen in the second quarter worth $156,812,000. Finally, Assenagon Asset Management S.A. raised its position in Amgen by 1,505.3% in the second quarter. Assenagon Asset Management S.A. now owns 518,604 shares of the medical research company’s stock worth $144,799,000 after acquiring an additional 486,299 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Morgan Stanley increased their price objective on Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. UBS Group dropped their price target on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a research report on Wednesday, August 6th. William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, June 24th. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Friday. Finally, Raymond James Financial started coverage on Amgen in a research report on Wednesday, September 3rd. They issued a “market perform” rating for the company. Seven research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $309.70.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.76% of the stock is owned by corporate insiders.

Amgen Stock Up 0.2%

Shares of NASDAQ:AMGN opened at $297.89 on Friday. The stock’s 50-day moving average price is $287.34 and its two-hundred day moving average price is $288.17. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $335.88. The firm has a market cap of $160.37 billion, a price-to-earnings ratio of 24.36, a PEG ratio of 2.59 and a beta of 0.49.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74. The business had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s payout ratio is currently 77.84%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.